ライフサイエンスコーパス: yttrium-aluminum-garnet

1 trials of alternative devices using holmium:yttrium-aluminum-garnet and eximer lasers are underway.

2 copic therapy, including formalin, neodymium/yttrium aluminum garnet, argon and potassium titanyl pho

3 lar lens (IOL) decentration, neodymium-doped yttrium aluminum garnet capsulotomy for posterior capsul

4 OL) was the most common (51.2%), followed by yttrium aluminum garnet capsulotomy, refractive surgery,

5 ery, 35.6% of patients underwent a neodymium:yttrium-aluminum-garnet capsulotomy in the iMics1 NY-60

6 significant difference in PCO and neodymium:yttrium-aluminum-garnet capsulotomy rate 3 years after s

7 of the optic disc was obscured, or neodymium-yttrium-aluminum-garnet capsulotomy was performed.

8 s (57.9%), 9 eyes (47.4%) required neodymium-yttrium-aluminum-garnet capsulotomy, and 3 eyes (15.8%)

9 Nd:YAG (neodymium:yttrium-aluminum-garnet) capsulotomy (Nd:YAG-caps) is th

10 ave demonstrated that a Q-switched neodymium:yttrium-aluminum-garnet dermatology laser kills larval m

11 lculated the modulation transfer function of yttrium-aluminum-garnet doped with cerium, anthracene, a

12 y aimed to assess the effect of erbium-doped yttrium aluminum garnet (Er:YAG) laser treatment on zirc

13 ith a single application of either an erbium:yttrium-aluminum-garnet (Er:YAG) (2,940-nm) laser or a d

14 ifferent photoablative dental lasers, erbium:yttrium-aluminum-garnet (Er:YAG) and diode, for the trea

15 l scaling and root planing and erbium-doped: yttrium-aluminum-garnet (Er:YAG) in the treatment of gen

16 The efficacy of erbium:yttrium-aluminum-garnet (Er:YAG) laser application as an

17 ventional ultrasonic scaler versus an erbium:yttrium-aluminum-garnet (Er:YAG) laser on titanium surfa

18 nt-like titanium surfaces by an erbium-doped yttrium-aluminum-garnet (Er:YAG) laser, titanium brush,

19 ities including carbon dioxide (CO2), erbium:yttrium-aluminum-garnet (Er:YAG), pulsed dye (PDL), and

20 Holmium:yttrium-aluminum-garnet (Ho:YAG) laser endoureterotomy i

21 ped by a commercial nanosecond holmium doped yttrium-aluminum-garnet (Ho:YAG) laser.

22 Swine underwent holmium:yttrium-aluminum-garnet (holmium:YAG) (n = 12) or carbon

23 Animals then underwent TMR with a holmium:yttrium-aluminum-garnet (holmium:YAG) laser (n = 5), TMI

24 The latter consisted of neodymium:yttrium-aluminum-garnet hyaloidotomy in the 5 eyes with

25 ration was stimulated in vivo with a Holmium:yttrium aluminum garnet laser (2.12 microm), free electr

26 aser photocoagulation and no neodymium-doped yttrium aluminum garnet laser capsulotomy.

27 In this study, picosecond neodymium:yttrium aluminum garnet laser treatment using a single f

28 tle evidence that using a diode or neodymium:yttrium-aluminum-garnet laser adds clinical value over a

29 he introduction of the side-firing neodymium:yttrium-aluminum-garnet laser in the early 1990s laser p

30 er-diameter optic fiber coupled to a holmium:yttrium-aluminum-garnet laser or a 400-micrometer-diamet

31 t, including thermal ablation with neodymium:yttrium-aluminum-garnet laser, argon plasma coagulation,

32 ise endoscopic lithotrites like the holmium: yttrium-aluminum-garnet laser.

33 itched, frequency-doubled Nd:YAG (neodymium, yttrium, aluminum, garnet) laser operating at 532 nm to

34 The holmium:YAG (Yttrium-Aluminum-Garnet) laser lithotripter is able to d

35 chial amyloidosis required Nd:YAG (neodymium:yttrium-aluminum-garnet) laser therapy for obstructive s

36 the combination of carbon dioxide and erbium:yttrium-aluminum-garnet lasers to achieve improved resul

37 derwent percutaneous Biosense-guided holmium:yttrium aluminum garnet LMR to areas of viable but ische

38 IOL placement, piggyback IOLs, and neodymium:yttrium-aluminum-garnet nasal capsulectomy.

39 through the performance of a neodymium-doped yttrium aluminum garnet (ND: YAG) laser capsulotomy with

40 Neodymium:yttrium aluminum garnet (Nd:YAG) laser capsulotomy is a

41 n from a handheld Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser pulse device used

42 A 532 nm frequency doubled neodymium-doped yttrium aluminum garnet (ND:YAG) laser was used to creat

43 cumulative incidences of PCO and subsequent yttrium-aluminum-garnet (Nd:YAG) capsulotomy over the 5-

44 (1) To report the neodymium:yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulo

45 Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser treatment is perf

46 llow-emitting phosphor, such as cerium-doped yttrium aluminum garnet or (YAG):Ce(3+), coupled with a

47 Neodymium-doped yttrium aluminum garnet posterior capsulotomy rates for

48 Additional procedures, such as yttrium aluminum garnet (YAG) capsulotomies or reduction

49 The renowned yellow phosphor yttrium aluminum garnet (YAG) doped with trivalent ceriu

50 int-based models to resolve RUS spectra from yttrium-aluminum-garnet (YAG) ceramic samples with three

51 r capsular opacification and neodymium-doped yttrium-aluminum-garnet (YAG) laser capsulotomy, and sur

52 Medicare beneficiary proximity to his or her yttrium-aluminum-garnet (YAG) laser capsulotomy-providin

53 The mid-infrared holmium:yttrium-aluminum-garnet (YAG) laser has been shown to be

54 silluminator, 488-nm argon-ion laser, 532-nm yttrium-aluminum-garnet (YAG) laser, blue fluorescent li